This three-part series will delve into behind-the-scenes strategies in oncology drug design and development, offering expert insight into the next-generation landscape.
PURPOSEAcral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low…
PURPOSETo assess the impact and outcomes of a novel program for routine preemptive DPYD testing in fluoropyrimidine (FP)-naïve patients.PATIENTS AND METHODSThis single-center, retrospective cohort study…
In the current evolving landscape of cancer treatment, the notion that all patients with advanced cancer, but especially those with rare cancers, must receive comprehensive…
Universal germline and tumor genomic testing needed to win the war against cancer.
This Viewpoint argues for universal tumor sequencing.
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the…
Circulating tumour DNA (ctDNA)-based detection of molecular residual disease (MRD) presents a strategy to identify patients at high risk of relapse. In this article, we…
TPS3185Background: Human epidermal growth factor receptor 2 (HER2) gene mutations occur in approximately 3.5% of solid tumors, with a frequency varying from less than 1%…
Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options…
TPS3185Background: Human epidermal growth factor receptor 2 (HER2) gene mutations occur in approximately 3.5% of solid tumors, with a frequency varying from less than 1%…
